EYPT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
EyePoint Inc (EYPT) is not a strong buy for a beginner, long-term investor at this moment. Despite positive analyst ratings and a promising pipeline, the company's recent financial performance and technical indicators suggest caution. The stock has experienced significant price volatility, and there are no strong proprietary trading signals or immediate catalysts to justify an entry point now.
The stock's MACD is positive but contracting, RSI is neutral at 35.938, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading near its support level (S1: 15.008), with a significant recent price drop of -12.44%. This indicates potential instability in the short term.
Analysts have raised price targets recently, with a consensus Buy rating. EyePoint's Phase 3 trials for diabetic macular edema and a strong cash position of $306 million are positive indicators for long-term growth.
The company reported a 94.7% YoY revenue decline in Q4 2025 and ongoing challenges in profitability (GAAP EPS of -$0.81). The stock has also experienced significant recent price volatility (-12.44% in regular market trading).
In Q4 2025, revenue dropped significantly (-94.7% YoY), and net income remained negative at -$59.73 million. While EPS improved slightly YoY, gross margin fell drastically to 25.36%. These metrics indicate financial instability.
Analysts remain bullish, with recent price target increases (e.g., H.C. Wainwright raised to $30, Chardan to $29, Mizuho to $36). The company's Phase 3 program has been positively factored into valuations, but competition and regulatory timelines remain concerns.
